Tolerance of one benzodiazepine does not reliably predict tolerance of every other member.
A case of suspected remimazolam anaphylaxis included allergy investigation and an earlier reaction during midazolam-containing anesthesia. The patient had tolerated brotizolam, raising questions about selective or variable cross-reactivity.
Testing supported remimazolam as a suspected allergen, and a prior reaction during midazolam exposure raised concern about cross-reactivity. The patient had also tolerated brotizolam. These observations argue against assuming that every benzodiazepine will necessarily behave identically in that patient. They also do not establish that an untested alternative is safe: the case illustrates an incomplete and individualized pattern, not a validated class-wide prediction rule.
A case and small literature review cannot define a universal cross-reactivity map. Testing methods, excipients and other agents need consideration, and a past reaction’s cause may remain uncertain.
Record the exact drugs and formulations rather than using a broad allergy label without qualification. Prior tolerance is useful history but does not settle a later perioperative reaction. The report cannot determine the safe alternative for another patient without an individualized clinical evaluation.
Source: PMC11161983, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Intranasal Midazolam–Lidocaine Trial Did Not Establish Noninferiority Despite Similar Scores.